Replies to post #413861 on Amarin Corp Plc (AMRN)

[TCI1]

Thanks for getting back. Given the agreement extract that Lizzy posted which referred to indications & research already underway by Mochida and given JT mentioned development of FDC and MND-2119 in an investor call it would appear that Amarin does have rights, assuming they continued to meet their obligations under the agreement such as payments. It would be good to get confirmation from Amarin, however the possibility of a new once a day 2 capsule drug would be so transformative it would be kept under wraps until the very last moment. It should recapture the market as we should be able to undercut generics on pricing. The issue is it is difficult to release this information when reimbursement discussions are ongoing in Europe and ROW.